
FDA knocks back Alkermes’ opioid-based depression therapy over lack of evidence
pharmafile | February 4, 2019 | News story | Sales and Marketing |Â Â Alkermes, FDA, major depressive disorder, pharma, rejectionÂ
Alkermes experimental opioid-based depression therapy ALKS 5461 has been rejected by the FDA, it has emerged, in the adjunctive treatment of major depressive disorder (MDD).
The US agency confirmed the decision in a complete response letter, refusing to approve the drug in its current form. Alkermes has been requested to provide additional data to support its efficacy, and the company, in turn, confirmed that it would meet with the FDA to discuss how these concerns could be rectified.
The manufacturer did not state whether it would continue development of the therapy, only noting that this decision will be taken in light of its meeting with the FDA.
The FDA’s rejection comes after strong opposition from an agency advisory panel which questioned both the product’s safety and efficacy.
The drug, a once-daily combination of samidorphan and buprenorphine, is aiming to become the first opioid-based treatment approved for MDD, a condition which affects 16.2 million in the US alone, two-thirds of which do not respond to currently available therapies.
Matt Fellows
Related Content

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …





